EUR 2.85
(-2.9%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 131.31 Million CAD | 30.08% |
2022 | 100.95 Million CAD | 57.78% |
2021 | 63.98 Million CAD | 107.66% |
2020 | 30.81 Million CAD | 172.29% |
2019 | 11.31 Million CAD | 263.89% |
2018 | 3.1 Million CAD | -33.95% |
2017 | 4.7 Million CAD | 9.55% |
2016 | 4.29 Million CAD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q3 | 35.45 Million CAD | 0.44% |
2024 Q2 | 35.29 Million CAD | -1.93% |
2024 Q1 | 35.99 Million CAD | 9.13% |
2023 Q3 | 34.57 Million CAD | 9.53% |
2023 Q2 | 31.56 Million CAD | -1.9% |
2023 Q1 | 32.18 Million CAD | 9.02% |
2023 FY | 131.31 Million CAD | 30.08% |
2023 Q4 | 32.98 Million CAD | -4.61% |
2022 Q3 | 25.75 Million CAD | 13.49% |
2022 Q1 | 22.98 Million CAD | 31.04% |
2022 Q4 | 29.51 Million CAD | 14.61% |
2022 FY | 100.95 Million CAD | 57.78% |
2022 Q2 | 22.69 Million CAD | -1.25% |
2021 Q1 | 14.76 Million CAD | 56.79% |
2021 Q3 | 16.67 Million CAD | 11.21% |
2021 Q4 | 17.53 Million CAD | 5.15% |
2021 Q2 | 14.99 Million CAD | 1.56% |
2021 FY | 63.98 Million CAD | 107.66% |
2020 FY | 30.81 Million CAD | 172.29% |
2020 Q2 | 7.38 Million CAD | 54.66% |
2020 Q4 | 9.41 Million CAD | 2.07% |
2020 Q1 | 4.77 Million CAD | 16.12% |
2020 Q3 | 9.22 Million CAD | 24.91% |
2019 Q3 | 3.06 Million CAD | 30.16% |
2019 FY | 11.31 Million CAD | 263.89% |
2019 Q4 | 4.11 Million CAD | 34.44% |
2019 Q2 | 2.35 Million CAD | 31.37% |
2019 Q1 | 1.78 Million CAD | 431.21% |
2018 Q3 | 1.17 Million CAD | 40.79% |
2018 Q2 | 836 Thousand CAD | -42.43% |
2018 FY | 3.1 Million CAD | -33.95% |
2018 Q4 | -540.31 Thousand CAD | -145.91% |
2018 Q1 | 1.45 Million CAD | 8.28% |
2017 Q3 | 1.65 Million CAD | 0.0% |
2017 Q4 | 1.34 Million CAD | -18.86% |
2017 FY | 4.7 Million CAD | 9.55% |
2016 FY | 4.29 Million CAD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 9.05 Million EUR | -1349.862% |
Redcare Pharmacy NV | 440.38 Million EUR | 70.182% |